Login
Search
Search
0 Dates
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Ejection Fraction in Heart Failure and Intensive Care Admission: What is the Prognostic Impact?
Session:
SESSÃO DE POSTERS 21 - IC E PROGNÓSTICO
Speaker:
Rita Ventura
Congress:
CPC 2025
Topic:
D. Heart Failure
Theme:
11. Acute Heart Failure
Subtheme:
11.2 Acute Heart Failure – Epidemiology, Prognosis, Outcome
Session Type:
Cartazes
FP Number:
---
Authors:
Rita Bertão Ventura; Mafalda Griné; Inês Brito e Cruz; Maria João Primo; Didier Martinez; Tomás Carlos; Luísa Rocha; Bernardo Resende; Catarina Mendes Silva; Manuel Oliveira-Santos; Lino Gonçalves
Abstract
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><strong>Introduction:</strong> The impact of ventricular dysfunction on the prognosis of heart failure (HF) patients admitted to the Intensive Care Unit remains unclear. This study aimed to characterize ICU HF patients and assess the prognostic impact of ventricular dysfunction stratified by ejection fraction (EF).</span></span></p> <p style="text-align:justify"> </p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><strong>Methods: </strong>This was a single-centre retrospective cohort study analyzing patients admitted to the ICU with HF at admission between 2020 and 2023. Patients were categorized into three groups based on EF: preserved EF (pEF), mildly reduced EF (mrEF), and reduced EF (rEF). A descriptive analysis of the study population was conducted. This included the type of admission, the need for organ support (such as ECMO and vasopressors), the presence of cardiogenic shock, and laboratory parameters, like lactate and BNP levels. The primary endpoint was all-cause mortality at 30 days and 1 year. Secondary endpoints included rehospitalization rates at 30 days and 1 year, ICU length of stay, and total hospital length of stay.</span></span></p> <p style="text-align:justify"> </p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><strong>Results: </strong>A total of 135 patients (mean age 66.5 ± 13.0 years, 68.1% male) were included in the study. Of these, 96 (71.1%) were admitted for medical reasons, 37 (27.4%) for emergency surgery, and 2 (1.5%) for scheduled surgery. The patients were categorized into 3 groups: pEF (n=59, 43.7%), mrEF (n=23, 17.0%), and rEF (n=53, 39.3%). The use of ECMO differed significantly between the groups (p=0.012), being more frequent in rEF (n=6, 11.3%; p=0.036) and mrEF (n=5, 21.7%; p=0.006) compared to pEF (n=1, 1.7%). Similarly, vasopressor use showed significant differences (p=0.043), with rEF (n=51, 96.2%) using vasopressors more frequently than pEF (n=49, 83.1%; p=0.032). Significant differences were observed in lactate (p=0.008) and BNP (p=0.046) levels. Cardiogenic shock was significantly more common in rEF (n=31, 58.5%) than in pEF (n=9, 15.3%; p<0.001) and mrEF (n=7, 30.4%; p=0.045). No statistically significant differences were found in 30-day mortality (p=0.631) or 1-year mortality (p=0.085) between groups. Likewise, rehospitalization rates at 30 days (p=1.000) and 1 year (p=0.716) were comparable. Additionally, ICU and total hospital length of stay did not differ significantly (p=0.316 and p=0.185).</span></span></p> <p style="text-align:justify"> </p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><strong>Conclusion: </strong>The study suggests that while ventricular dysfunction was associated with increased use of advanced therapies such as ECMO and vasopressors, as well as more severe clinical presentation, it did not significantly affect short- or long-term survival. </span></span></p> <p style="text-align:justify"> </p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site